Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-cash Items (2019 - 2025)

Historic Non-cash Items for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $6.0 million.

  • 4D Molecular Therapeutics' Non-cash Items rose 4539.81% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 4539.81%. This contributed to the annual value of $54.5 million for FY2024, which is 164094.43% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Non-cash Items stood at $6.0 million, which was up 4539.81% from $5.5 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Non-cash Items' 5-year high stood at $54.5 million during Q4 2024, with a 5-year trough of $1.4 million in Q2 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Non-cash Items averaged around $11.6 million, with its median value being $3.3 million (2024).
  • In the last 5 years, 4D Molecular Therapeutics' Non-cash Items plummeted by 7459.86% in 2021 and then surged by 9480.26% in 2022.
  • Over the past 5 years, 4D Molecular Therapeutics' Non-cash Items (Quarter) stood at $24.7 million in 2021, then skyrocketed by 94.8% to $48.0 million in 2022, then dropped by 2.47% to $46.9 million in 2023, then increased by 16.3% to $54.5 million in 2024, then tumbled by 88.96% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $5.5 million for Q2 2025, and $5.0 million during Q1 2025.